The EU’s IP strategy: Enabler or barrier?
27 October 2020
Our second dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
How do we ensure that IP incentives compensate and reward innovation but do not distort competition?
What lessons have we learned on IP in the response to COVID-19?
Patent-driven innovation may work for profit-driven drug development but it reflects a R&I agenda which favours profit prospects, distortion of competition and market dominance. Additionally, it leads to excessive, unaffordable prices due to monopoly and can stifle meaningful innovation.
As the EU prepares to present its IP strategy as well as the scenarios for a review of the legislation on orphan and paediatric medicines, join our experts and key stakeholders who will discuss what change is necessary to serve the needs of all patients while guaranteeing healthy prices and competition.
Policy Officer, DG Internal Market, Industry, Entrepreneurship and SMEs (DG Growth), European Commission
EU Policy & Advocacy Advisor, Médecins Sans Frontières Access Campaign
General Counsel & External Relations Director, Medicines for Europe
Thyra de Jongh
Principal Consultant, Technopolis Group
EPHA’s series of online discussions on key access to medicines (A2M) priorities brings together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.